Diagnostic and prognostic value of a disintegrin and metalloproteinase‑17 in patients with gliomas

Wu,Bin; Sha,Longgui; Wang,Yong; Xu,Wei; Yu,Yang; Feng,Fang; Sun,Caixing; Xia,Liang

doi:10.3892/ol.2014.2582

December-2014 Volume 8 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December-2014 Volume 8 Issue 6

Full Size Image

Article

Diagnostic and prognostic value of a disintegrin and metalloproteinase‑17 in patients with gliomas

Authors:
- Bin Wu
- Longgui Sha
- Yong Wang
- Wei Xu
- Yang Yu
- Fang Feng
- Caixing Sun
- Liang Xia
View Affiliations / Copyright

Affiliations: Department of Neurosurgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Department of Neurosurgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, Shanghai 200120, P.R. China, Department of Neurosurgery, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Pages: 2616-2620
|
Published online on: October 1, 2014

https://doi.org/10.3892/ol.2014.2582
Expand metrics +

Abstract

A disintegrin and metalloproteinase‑17 (ADAM17) has been shown to regulate numerous proteins involved in the cell cycle, as well as tumor oncogenes. The expression pattern of ADAM17 in glioma patients, however, is unclear. In the present study, the expression pattern and prognostic significance of ADAM17 was investigated in patients with glioma. A total of 60 glioma specimens and eight normal control samples were obtained. Immunohistochemical and western blot analyses were used to examine the expression of ADAM17. In addition, the association of ADAM17 expression with the clinicopathological parameters and the survival rates of the glioma patients was analyzed. The results showed that ADAM17 was upregulated in the high‑grade glioma tissues compared with that in the low‑grade and normal brain tissues of the glioma patients, and that the level increased with ascending World Health Organization tumor grade (P<0.05). Furthermore, the survival rate of the patients with ADAM17‑positive tumors was lower compared with the patients with ADAM17‑negative tumors. These results indicated that the overexpression of ADAM17 was correlated with a high tumor grade and a poor prognosis in patients with glioma. ADAM17 may have an important oncogenic function in glioma progression, and is a potential diagnostic and therapeutic target.

View Figures

View References

1	Mercer RW, Tyler MA, Ulasov IV and Lesniak MS: Targeted therapies for malignant glioma: progress and potential. Biodrugs. 23:25–35. 2009.
2	Demuth T and Berens ME: Molecular mechanisms of glioma cell migration and invasion. J Neurooncol. 70:217–228. 2004.
3	Warren KE: Diffuse intrinsic pontine glioma: poised for progress. Front Oncol. 2:2052012.
4	Ortega-Aznar A, Jimenez-Leon P, Martinez E and Romero-Vidal FJ: Clinico-pathological and molecular aspects of diagnostic and prognostic value in gliomas. Rev Neurol. 56:161–170. 2013.(In Spanish).
5	Carl-McGrath S, Lendeckel U, Ebert M, Roessner A and Rocken C: The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 26:17–24. 2005.
6	Kanda K, Komekado H, Sawabu T, et al: Nardilysin and ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via enhanced ectodomain shedding of TNF-α. EMBO Mol Med. 4:396–411. 2012.
7	Meng P, Yoshida H, Matsumiya T, et al: Carnosic acid suppresses the production of amyloid-β 1–42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SY5Y human neuroblastoma cells. Neurosci Res. 75:94–102. 2013.
8	Borrell-Pagès M, Rojo F, Albanell J, Baselga J and Arribas J: TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J. 22:1114–1124. 2003.
9	Gao MQ, Kim BG, Kang S, et al: Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-α cleavage by ADAM17. Cancer Lett. 336:240–246. 2013.
10	Ni SS, Zhang J, Zhao WL, Dong XC and Wang JL: ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival. Tumour Biol. 34:1813–1818. 2013.
11	Shou ZX, Jin X and Zhao ZS: Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann Surg. 256:1014–1022. 2012.
12	Chen X, Chen L, Chen J, et al: ADAM17 promotes U87 glioblastoma stem cell migration and invasion. Brain Res. 1538:151–158. 2013.
13	Alexandru D, Haghighi B and Muhonen MG: The treatment of angiocentric glioma: case report and literature review. Perm J. 17:e100–e102. 2013.
14	Ahluwalia MS and Gladson CL: Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol. 2010:6890182010.
15	Klein T and Bischoff R: Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure. J Proteome Res. 10:17–33. 2011.
16	Lu X, Lu D, Scully M and Kakkar V: ADAM proteins - therapeutic potential in cancer. Curr Cancer Drug Targets. 8:720–732. 2008.
17	McGowan PM, Ryan BM, Hill AD, et al: ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res. 13:2335–2343. 2007.
18	Kornfeld JW, Meder S, Wohlberg M, Friedrich RE, et al: Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer. 104:138–145. 2011.
19	Petrás M, Lajtos T, Friedländer E, et al: Molecular interactions of ErbB1 (EGFR) and integrin-beta1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance. Neuro Oncol. 15:1027–1040. 2013.
20	Huang PH, Xu AM and White FM: Oncogenic EGFR signaling networks in glioma. Sci Signal. 2:re62009.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Diagnostic and prognostic value of a disintegrin and metalloproteinase‑17 in patients with gliomas

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles